Navigation Links
Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
Date:1/22/2008

TORONTO, Jan. 22 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR; AMEX: LRP), a biopharmaceutical company dedicated in the research and development of pharmaceutical products and technologies for the management of cancer, announced today that it has strengthened its management team with the appointment of Mr. Peter Korth to the post of Chief Financial Officer (CFO).

Mr. Korth has previously held senior financial and business development positions including CFO in several private and public companies including DRI Capital (formerly known as Drug Royalty Corp.), Clean Power Income Fund, TransAlta Corporation and Indal Limited where he has been responsible for capital and credit markets, transaction structuring, managing subsidiary reorganizations, risk management practices as well as international business development in Asia and Australia.

"Mr. Korth brings significant expertise in corporate finance, investor relations, corporate governance and compliance to the management team at Lorus," said Dr. Aiping Young, Lorus' President and CEO. "We believe Lorus will benefit from Peter's track record in developing and bringing an exemplary combination of business judgment, professional skills and integrity."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus has completed one Phase II and one Phase III clinical trial. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward looking statements '/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and BOSTON , Oct. ... ), a leading global specialty pharmaceutical company, and Rhythm, ... granted an exclusive option to acquire Rhythm,s wholly owned ... a peptide ghrelin agonist, for the treatment of diabetic ... Rhythm has completed a successful Phase 2 trial of ...
(Date:10/22/2014)... 22, 2014 Involution Studios , ... of a new infographic, Understanding Ebola . ... beautifully designed, easy to follow informative tool for anyone ... outbreak, symptoms and prevention. , "As the news has ... 2014 Ebola outbreak represents not only a healthcare crisis ...
(Date:10/22/2014)... Rock Hill, SC (PRWEB) October 22, 2014 ... the expansion of its cardiovascular pharmacogenetics menu, which ... improved patient outcomes. With PCLS’s evidence-based results, ... individual needs and optimize their therapy, while minimizing ... , In the U.S., according to the FDA ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... Diabetes Federation, approximately 400 million people worldwide are living ... 552 million people by 2030.  The global market for ... In 2012 approximately 330,000 people worldwide died from pancreatic ... of death due to cancer in the ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... 2011 Interleukin Genetics, Inc. (OTCQB: ILIU) announced ... Wedbush Securities Life Sciences Management Access Conference at the Le ... City. The presentation is scheduled for Wednesday, Aug. 17 at ... second floor.   Interleukin,s management team will be ...
... Mass., Aug. 10, 2011 Boston Scientific Corporation (NYSE: ... Institute™ (NLI), a clinical education program and online resource ... awareness of spinal cord stimulation (SCS) technology, procedures and ... meeting of the International Spine Intervention Society (ISIS) occurring ...
... DIEGO, Aug. 9, 2011 Verenium Corporation (Nasdaq: ... development and commercialization of high-performance enzymes, today reported a summary ... quarter and six months ended June 30, 2011. ... terms of product revenues and partnership negotiations in the first ...
Cached Biology Technology:Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference 2Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 2Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 3Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 2Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 5Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 6Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 7Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 8Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 9
(Date:10/17/2014)... from the University of Copenhagen have shown for the ... lungs of Cystic fibrosis patients, giving them the opportunity ... in chronic infections. , The study also discovered the ... (CF) patients was halted or slowed down by the ... all the oxygen and helped "suffocate" the bacteria, forcing ...
(Date:10/16/2014)... Oregon and Washington land managers have a new synthesis ... eastside moist mixed-conifer (MMC) forests in the two states. ... Forests in Eastern Oregon and Washington: A Synthesis of ... Management, a general technical report published by the U.S. ... response to a request from managers for a synthesis ...
(Date:10/16/2014)... 2014) – Post-menopausal women experienced improvements in vaginal ... or genital bleeding, after 12 weeks of daily ... soy germ-based nutritional supplement previously shown to help ... peer-reviewed pilot study reported in a poster at ... meeting. , "These data documented improved vaginal ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2New report synthesizes best available science on management of moist mixed-conifer forests 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... the Department of Agriculture and Food Western Australia (DAFWA) ... Australia,s worst agricultural weeds. , "We are initiating a ... to control one and two-leaf Cape tulips (Moraea flaccida ... as a biological control agent," CSIRO Entomology,s Dr John ...
... on the miracle of life. The joining of egg and ... if the chromosome information from each parent has been translated ... is that when extra copies of chromosomes or fewer than ... birth defects can occur. Now, scientists at the University of ...
... may study grasses by profession, but Texas AgriLife Research forage agronomist Dr. Dariusz Malinowski ... And it is that ... Malinowski ... with his master,s degree in horticulture. , ...
Cached Biology News:Cape tulips -- pretty but pests in pastures 2UGA researchers propose model for disorders caused by improper transmission of chromosomes 2UGA researchers propose model for disorders caused by improper transmission of chromosomes 3Unique winter-hardy hibiscus has roots with AgriLife Research scientist in Vernon 2Unique winter-hardy hibiscus has roots with AgriLife Research scientist in Vernon 3
... preparations are prepared from customers high-copy ... to multi-gram scales. Each preparation is ... glycerol stocks are maintained to facilitate ... (Clonal selection includes screening colonies for ...
... channels for automated gigaseal patch clamping. ... voltage-gated ion channels, such as hERG and ... The four pipette heads afford more efficient ... drug discovery. The glass-coated tunnels of ...
... be able to handle larger sample volumes, automate ... as interface with telemetry systems. The AccuSampler ... dogs, pigs, and primates. The system may ... the computer can be located outside the animal ...
... The GST•Tag™ Antibody Plate is ... GST•Tag Monoclonal Antibody. This antibody (mouse ... S. japonicum glutathione-S-transferase (GST), ... virtually any GST•Tag fusion protein in ...
Biology Products: